Evidence map›Paper›PMID 42343697›Full record

ReviewChinese medical journal2026

Mitochondrial quality control in health and disease: Updates 2026.

Zhengzhao Liu, Wenbao Hu, Lin Sun, Huafeng Liu

Abstract readReview
In one paragraph

Review in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhengzhao LiuDepartment of Nephrology, National Clinical Key Specialty Construction Program (2023); Institute of Nephrology; Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases; Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City; Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China.
Wenbao HuDepartment of Nephrology, National Clinical Key Specialty Construction Program (2023); Institute of Nephrology; Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases; Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City; Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China.
Lin SunDepartment of Nephrology, Key Laboratory of Kidney Disease and Blood Purification, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China.
Huafeng LiuDepartment of Nephrology, National Clinical Key Specialty Construction Program (2023); Institute of Nephrology; Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases; Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City; Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractMitochondria are central to cellular energy metabolism, and their functional integrity is essential for maintaining cellular homeostasis and life processes. Mitochondrial quality control (MQC) encompasses a complex network of mechanisms-including mitochondrial biogenesis, mitochondrial dynamics, mitophagy, mitochondrial proteostasis, and mitochondrial-derived vesicles-that collectively preserve the structural and functional balance of mitochondria. Recent studies have revealed that dysregulation of MQC is closely associated with a broad spectrum of diseases, such as neurodegenerative disorders, cardiovascular diseases, kidney diseases, metabolic syndrome, and cancers, highlighting its critical role in pathological processes. Despite significant progress in elucidating the molecular regulation of MQC, many aspects of its complexity and multilayered regulatory mechanisms remain unresolved. This review provides a comprehensive overview of the major molecular pathways involved in MQC and their functional alterations under physiological and pathological conditions. It emphasizes the abnormalities of MQC in various diseases and explores potential therapeutic targets. Moreover, integrating the latest research advances, this article discusses emerging treatment strategies aimed at restoring and optimizing MQC, with the goal of offering theoretical insights and clinical translation avenues for future disease prevention and management.

Indexed as

MitochondriaAnimalsHumansMitochondrial DynamicsMitophagyNeurodegenerative DiseasesCardiovascular diseaseKidney diseaseMitochondriaMitochondrial dynamicsMitochondrial quality controlMitophagyNeurodegenerative diseaseTherapeutic strategies

Identifiers

PMID42343697
PMCPMC13626680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.